Aradigm

Aradigm is actively involved in fulfilling the commitment to developing inhalation medication products that could potentially transform the quality of life for patients with severe pulmonary conditions. Since 1991, the organization has assembled an exceptional group of researchers, technicians, and medical specialists who have been leading the way in the creation of innovative inhalation delivery products. This team, for instance, spearheaded the AERx® pulmonary delivery platform, which underwent testing in numerous patients using various medications and biologics such as insulin, fentanyl, erythropoietin, and nicotine.